资讯

行业新闻

与原料药、中间体及成品制剂伙伴相关的授权交易、监管决策与市场动态。

2026.06.26industry

Biogen Pauses Majority of Apellis Pipeline After $5.6B Buyout, Signaling Post-M&A Rationalization Wave

Biogen cancels most R&D programs from its $5.6B Apellis acquisition and lays off staff, concentrating on marketed Empaveli and Syfovre — a cautionary signal for API suppliers tied to early-stage pharma programs.

2026.06.26industry

Merck KGaA's $11.3B Bio-Techne Buyout Reshapes Life Sciences Tools Supply Chain

Merck KGaA acquires Bio-Techne for $11.3B, its largest deal in a decade, consolidating life sciences reagents, spatial biology, and diagnostics under one roof with implications for pharma supplier relationships.

2026.06.25industry

Novartis Bets $105M on Small Molecule Revival with Antares Discovery Pact

Novartis commits $105M upfront in a small molecule drug discovery collaboration with Antares, signaling renewed big pharma confidence in traditional chemistry and sustained API demand.

2026.06.25industry

HHS Unveils Blueprint to Fast-Track Early Drug Research, Aims to Counter China's Clinical Trial Edge

HHS publishes a comprehensive reform blueprint streamlining IND applications and clinical trial processes, directly responding to China's 18-month discovery-to-clinic advantage and its impact on pharmaceutical supply chains.

2025.06.30industry

Global Pharmaceutical Licensing Trends, H1 2025

Cross-border licensing deal value passed $38 billion in the first half of 2025, with risk-sharing structures displacing upfront-heavy terms and Asia-Pacific originators exporting assets to Western markets on increasingly favourable terms.

2025.06.20industry

Kv1.3 as a Licensing Target: Where the Partners Are and What They Want

More than 15 clinical-stage Kv1.3 programs are running worldwide, and regional licensees want structurally different deals. A review of what North American, European and Asia-Pacific partners prioritise, and how term structure affects completion rates.

我们能如何帮助您？

获取最新活动与法规动态洞察

直接发送到您的邮箱

在此获取行业洞察与 Unibest 动态

联系我们 →